Johnson & Johnson announced on Apr. 14 that it has raised its full-year 2026 revenue guidance to $100.8 billion after reporting a strong start to the year with first-quarter earnings of $24.1 billion.
The company’s new goal, if achieved, would mark the first time Johnson & Johnson reaches $100 billion in annual revenue and could help maintain its position as the top pharmaceutical company by revenue.
Chief Executive Officer Joaquin Duato said during an investor call, “We are on track to meet our 2026 target of $100 billion in annual revenue for the first time.” He added that J&J is “off to a fast start in 2026.” The company reported sales growth of 9.9% and operational growth of 6.4% in the first quarter.
Analysts described J&J’s results as a "modest beat," driven by oncology and neuroscience products within innovative medicines, as well as improved commercial execution and innovation in MedTech. Guggenheim noted that higher sales from the Innovative Medicine segment contributed to surpassing their estimate for quarterly earnings.
Key products led performance this quarter: Darzalex generated just under $4 billion in sales while Tremfya brought in around $1.6 billion worldwide. In addition, J&J highlighted several product approvals including Icotyde for moderate-to-severe plaque psoriasis—the first targeted anti-IL-23 therapy approved by the FDA for this condition—and a combination therapy (Darzalex Faspro plus Tecvayli) for second-line treatment of relapsed/refractory multiple myeloma under the FDA's Commissioner’s National Priority Voucher program.
During the call, Duato told investors that J&J currently has 28 programs or products, describing it as "the strongest pipeline" in its history spanning more than a century.
Looking ahead, J&J plans an Enterprise Business Review on December 8 when progress toward its ambitious annual revenue objective will be assessed.
